The National Institute for Health and Care Excellence (NICE) of the United Kingdom recommended on April 12, 2022 to offer TCZ to hospitalized adults with COVID-19 who are having or have completed a course of corticosteroids, did not receive another IL-6 inhibitor, and had no evidence of a bacterial or other viral infection. Here, IL6 is linked to viral infectious disease.